Life Sciences M&A

• EQRx in its sale to Revolution Medicines in an all-stock transaction to transfer more than US$1 billion in capital
• Orchard Therapeutics in its cross-border sale to Kyowa Kirin for US$390 million in upfront cash plus contingent value rights (CVRs)
• Graphite Bio in its reverse merger with LENZ Therapeutics and concurrent private placement financing
• RA Capital Management in connection with Eliem Therapeutics’ acquisition of Tenet Medicines and concurrent US$120 million private placement
• Korro Bio in its reverse merger with Frequency Therapeutics, concurrent US$117 million private placement financing, and CVRs
• Forma Therapeutics in its US$1.1 billion sale to Novo Nordisk
• Concert Pharmaceuticals in its cross-border sale to Sun Pharma for US$576 million in upfront cash plus CVRs
• TCR² Therapeutics in its cross-border, all-stock combination with Adaptimmune Therapeutics
• Surface Oncology in its sale to Coherus BioSciences for stock consideration and CVRs
• Checkmate Pharmaceuticals in its US$250 million sale to Regeneron Pharmaceuticals
• VBL Therapeutics in its reverse merger with Notable Labs and concurrent private placement financing
• Xeris Pharmaceuticals in its cross-border acquisition of Strongbridge Biopharma for stock and CVRs valued at US$267 million
• EryDel in its cross-border sale to Quince Therapeutics
• Neos Therapeutics in its all-stock merger with Aytu BioScience
• PAREXEL in its US$5 billion sale to Pamplona Capital Management in a "going private" transaction
• Ipsen in its cross-border acquisition of Clementia Pharmaceuticals for up to US$1.3 billion in upfront cash and CVRs
• Dimension Therapeutics in its proposed sale to RegenxBio and subsequent acceptance of topping bid from, and US$151 million sale to, Ultragenyx
• Ocera Therapeutics in its sale to Mallinckrodt for up to US$117 million in upfront cash and CVRs
• Morgan Stanley in its role as financial advisor to Stemcentrx in its US$5.8 billion sale to AbbVie
• Ocata Therapeutics in its US$380 million sale to Astellas Pharma
• Teva Pharmaceutical Industries in its disposition of certain assets to Ignyta
• Concert Pharmaceuticals in its disposition of certain assets to Vertex Pharmaceuticals
• Zoll Medical in its US$2.21 billion sale to Asahi Kasei Corporation
• Covidien in its US$250 million acquisition of Somanetics
• Aerpio Pharmaceuticals in its reverse merger with Aadi Bioscience, concurrent US$155 million PIPE financing, and CVRs
• resTORbio in its reverse merger with Adicet Bio, and CVRs
• Unum Therapeutics in its simultaneous sign and close reverse merger with Kiq, concurrent US$104 million PIPE financing, and CVRs
• Anelixis Therapeutics in its simultaneous sign and close reverse merger with Novus Therapeutics, and concurrent US$108 million PIPE financing
• Scienture in its simultaneous sign and close reverse merger with TRxADE HEALTH, and PIPE financing
• Zafgen in its reverse merger with Chondrial Therapeutics (operating as Larimar Therapeutics)
• Inotek Pharmaceuticals in its reverse merger with Rocket Pharma
• Precipio Diagnostics in its reverse merger with Transgenomic and related financing transaction

Technology, REITs and Other Industries M&A

• Virtusa in its US$2 billion sale to Baring Private Equity Asia in a "going private" transaction
• Leaf Group in its US$323 million sale to Graham Holdings Company
• LaSalle Hotel Properties in its response to unsolicited public acquisition proposals from Pebblebrook Hotel Trust, leading to its proposed US$4.8 billion sale to Blackstone in a “going private” transaction, and subsequent acceptance of topping bid from, and US$5.2 billion cash and shares acquisition by, Pebblebrook Hotel Trust
• Amplify Snack Brands (the maker of SkinnyPop popcorn) in its US$1.6 billion sale to Hershey
• Monotype in its US$825 million sale to HGGC in a "going private" transaction
• Control4 in its US$680 million sale to SnapAV, a portfolio company of Hellman & Friedman
• Imprivata in its US$544 million sale to Thoma Bravo in a "going private" transaction
• Opower in its US$532 million sale to Oracle
• Xoom in its US$890 million sale to PayPal
• Millennial Media in its US$248 million sale to AOL
• Paydiant in its sale to PayPal
• High Liner Foods in its US$230 million acquisition of Icelandic Group’s U.S. and Asia operations
• com in its sale to Kenexa
• The Princeton Review in its US$170 million acquisition of Penn Foster Education Group
• Candela in its sale to Syneron Medical
• Honest Tea in connection with a strategic investment by Coca-Cola
• Inverness Medical Innovations in its US$1.19 billion acquisition of Matria Healthcare
• Morgan Stanley Real Estate Fund in its US$6.5 billion acquisition of Crescent Real Estate Equities
• Brookfield Properties in its US$9.3 billion acquisition of Trizec Properties
• Beacon Capital Partners in its US$4.8 billion sale of private investment funds to Broadway Real Estate Partners

Proxy Contests and Other Shareholder Activism Defense Matters

• Anika Therapeutics in its defenses against, and entry into cooperation agreements with, Caligan Partners
• Rapid Micro Biosystems in its defense of an unsolicited takeover proposal by Kennedy Lewis Management, and its adoption of a limited duration stockholder rights plan
• WisdomTree Investments in its defenses against, and entry into cooperation agreements with, ETFS Capital Limited and Lion Point Capital, and its adoption of a limited duration stockholder rights plan
• KVH Industries its defense against, and entry into cooperation agreement with, Black Diamond Capital Management, and its adoption of a limited duration stockholder rights plan
• Cedar Realty Trust in its defense against, and entry into cooperation agreements with, Camac Partners and Ewing Morris & Co.
• Virtusa in its defense against, and entry into settlement agreement with, New Mountain Vantage Advisers
• Paramount Group in connection with an unsolicited acquisition proposal from Bow Street
• LaSalle Hotel Properties in its successful defense of activist campaigns led by HG Vora
• Monotype in its successful defense of a threatened proxy contest by Starboard Value
• Leaf Group in its successful defense of a threatened proxy contest by Osmium Partners
• AMAG Pharmaceuticals in its consent solicitation defense against, and entry into settlement agreement with, Caligan Partners
• Invesco Closed-end Funds trustees in response to shareholder proposals and nominations from, and entry into standstill agreement with, Saba Capital
• Cedar Realty Trust in the negotiation of a cooperation agreement with Snow Park Capital
• Cognizant in the negotiation of a cooperation agreement with Elliott Management
• PAREXEL in its defense of activist campaigns led by Corvex and Starboard Value
• A well-known closed-end fund in its response to shareholder proposals from, and entry into standstill agreement with, Saba Capital
• iRobot in its successful proxy contest concerning board representation against Red Mountain Capital
• CPS Technologies in its successful defense of a threatened proxy contest and "vote against" campaign by the Horton Group
• Brightcove in its entry into a cooperation agreement with, and subsequent successful defense of a threatened proxy contest by, Tenzing Global
• Monogram Residential Trust in its entry into a cooperation agreement with Snow Park Capital
• Relmada Therapeutics in its proxy contest and related litigation against Laidlaw, which sought unsuccessfully to replace a majority of the company’s board
• Lionbridge in its response to, and entry into a cooperation agreement with, Glen Capital Partners
• LoJack in its response to, and entry into a cooperation agreement with, Engine Capital
• Mac-Gray Corporation in its proxy contests against Moab Partners

Matters may have been handled prior to joining Paul Hastings.

• Member: American Bar Association